Prevalence of Candida glabrata and Its Response to Boric Acid Vaginal Suppositories in Comparison With Oral Fluconazole in Patients With Diabetes and Vulvovaginal Candidiasis
Authors:
Open Access
- 1 February 2007
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (2) , 312-317
Abstract
OBJECTIVE—A large proportion of vulvovaginal candidiasis (VVC) in diabetes is due to non–albicans Candida species such as C. glabrata and C. tropicalis. Observational studies indicate that diabetic patients with C. glabrata VVC respond poorly to azole drugs. We evaluated the response to oral fluconazole and boric acid vaginal suppositories in diabetic patients with VVC.Keywords
This publication has 25 references indexed in Scilit:
- Differential effect of insulin treatment on decreased levels of beta-defensins and Toll-like receptors in diabetic ratsMolecular Immunology, 2007
- Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapyJournal of Infection, 2006
- Azole Resistance in Candida glabrata : Coordinate Upregulation of Multidrug Transporters and Evidence for a Pdr1-Like Transcription FactorAntimicrobial Agents and Chemotherapy, 2004
- Species-specific Prevalence of Vaginal Candidiasis Among Patients with Diabetes Mellitus and its Relation to their Glycaemic StatusJournal of Infection, 2000
- Changing pattern of candida species in a bone marrow transplant patientJournal of Infection, 1996
- Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida.Sexually Transmitted Infections, 1995
- Characterization of an azole-resistant Candida glabrata isolateAntimicrobial Agents and Chemotherapy, 1992
- Risk Factors for Candida VulvovaginitisObstetrical & Gynecological Survey, 1992
- Best Subsets Logistic RegressionBiometrics, 1989
- The Yeast Flora of the Anogenital Region in Diabetic GirlsArchives of Dermatology, 1963